Switch theme
Sign up to access all valuation multiples
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
2005
674
LTM Revenue $651M
LTM EBITDA $161M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Supernus Pharmaceuticals has a last 12-month revenue of $651M and a last 12-month EBITDA of $161M.
In the most recent fiscal year, Supernus Pharmaceuticals achieved revenue of $662M and an EBITDA of $178M.
Supernus Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Supernus Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $608M | $662M | XXX | XXX | XXX |
| Gross Profit | $580M | $524M | XXX | XXX | XXX |
| Gross Margin | 95% | 79% | XXX | XXX | XXX |
| EBITDA | $90.0M | $178M | XXX | XXX | XXX |
| EBITDA Margin | 15% | 27% | XXX | XXX | XXX |
| Net Profit | $60.7M | $1.3M | XXX | XXX | XXX |
| Net Margin | 10% | 0% | XXX | XXX | XXX |
| Net Debt | $309M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Supernus Pharmaceuticals's stock price is $32.
Supernus Pharmaceuticals has current market cap of $1.8B, and EV of $1.3B.
See Supernus Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.8B | XXX | XXX | XXX | XXX | $2.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Supernus Pharmaceuticals has market cap of $1.8B and EV of $1.3B.
Supernus Pharmaceuticals's trades at 2.1x LTM EV/Revenue multiple, and 8.4x LTM EBITDA.
Analysts estimate Supernus Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Supernus Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 7.5x | XXX | XXX | XXX |
| P/E | 23.9x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 7.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSupernus Pharmaceuticals's NTM/LTM revenue growth is -2%
Supernus Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Supernus Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Supernus Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Supernus Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 98% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 25% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 34% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 77% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Supernus Pharmaceuticals acquired XXX companies to date.
Last acquisition by Supernus Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Supernus Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Supernus Pharmaceuticals founded? | Supernus Pharmaceuticals was founded in 2005. |
| Where is Supernus Pharmaceuticals headquartered? | Supernus Pharmaceuticals is headquartered in United States of America. |
| How many employees does Supernus Pharmaceuticals have? | As of today, Supernus Pharmaceuticals has 674 employees. |
| Who is the CEO of Supernus Pharmaceuticals? | Supernus Pharmaceuticals's CEO is Mr. Jack A. Khattar. |
| Is Supernus Pharmaceuticals publicy listed? | Yes, Supernus Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Supernus Pharmaceuticals? | Supernus Pharmaceuticals trades under SUPN ticker. |
| When did Supernus Pharmaceuticals go public? | Supernus Pharmaceuticals went public in 2012. |
| Who are competitors of Supernus Pharmaceuticals? | Similar companies to Supernus Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Supernus Pharmaceuticals? | Supernus Pharmaceuticals's current market cap is $1.8B |
| What is the current revenue of Supernus Pharmaceuticals? | Supernus Pharmaceuticals's last 12-month revenue is $651M. |
| What is the current EBITDA of Supernus Pharmaceuticals? | Supernus Pharmaceuticals's last 12-month EBITDA is $161M. |
| What is the current EV/Revenue multiple of Supernus Pharmaceuticals? | Current revenue multiple of Supernus Pharmaceuticals is 2.1x. |
| What is the current EV/EBITDA multiple of Supernus Pharmaceuticals? | Current EBITDA multiple of Supernus Pharmaceuticals is 8.4x. |
| What is the current revenue growth of Supernus Pharmaceuticals? | Supernus Pharmaceuticals revenue growth between 2023 and 2024 was 9%. |
| Is Supernus Pharmaceuticals profitable? | Yes, Supernus Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
